Autologous skin-derived neural precursor cell therapy reverses canine alzheimer dementia-like syndrome in a proof of concept veterinary trial

HIGHLIGHTS

SUMMARY

    Rodent studies have provided proof-of-concept using different cell types and models (reviewed by Duncan and amp; Valenzuela ), and a single Phase I clinical trial of direct brain injection of mesenchymal stromal cells (MSCs) found the procedure was safe but of no therapeutic consequence. Approximately 4-5 weeks post the first procedure, during which the SKN cells were manufactured, each patient underwent hippocampal microinjection of their autologous skin-derived neural precursor cells (SKNs) under general anaesthesia ("second procedure"). Rodent model of canine SKN cell engraftment Use of genetically non-modified autologous cells meant . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?